TABLE 5.
Use of coronavirus disease 2019 targeted therapies, immunosuppression, and antimicrobials during admission in eras 1 and 2
| Era 1 (March 1, 2020–May 31, 2020), n (%) | Era 2 (June 1, 2020–November 30, 2020), n (%) | P | |
|---|---|---|---|
| n | 21 | 56 | |
| MMF use at baseline | 13 (61.9) | 30 (53.6) | 0.6 |
| MMF resumed | 8 (66.7) | 9 (30.0) | 0.041 |
| Remdesivir | 0 (0.0) | 24 (42.9) | <0.001 |
| Hydroxychloroquine | 11 (52.4) | 0 (0.0) | <0.001 |
| Convalescent plasma | 4 (19.0) | 40 (71.4) | <0.001 |
| Tocilizumab | 5 (23.8) | 1 (1.8) | 0.005 |
| Dexamethasone | 0 (0.0) | 24 (42.9) | <0.001 |
| Empiric antibiotics | 19 (90.5) | 42 (75.0) | 0.21 |
| Antiviral | 8 (38.1) | 32 (57.1) | 0.20 |
| Antiviral: acyclovir | 6 (28.6) | 24 (42.9) | 0.30 |
| Antiviral: valacyclovir | 2 (9.5) | 13 (23.2) | 0.21 |
| Antiviral: ganciclovir | 2 (9.5) | 4 (7.1) | 0.7 |
| Antiviral: HIV antiretroviral therapy | 0 (0.0) | 3 (5.4) | 0.56 |
| Antiviral: entecavir | 0 (0.0) | 2 (3.6) | 1.0 |
| Antiviral: letermovir | 0 (0.0) | 3 (5.4) | 0.56 |
| Antifungal | 6 (28.6) | 17 (30.4) | 1.0 |
| Antifungal: isavuconazole | 3 (14.3) | 7 (12.5) | 1.0 |
| Antifungal: micafungin | 4 (19.0) | 5 (8.9) | 0.25 |
| Antifungal: posaconazole | 0 (0.0) | 6 (10.7) | 0.18 |
| Antifungal: fluconazole | 2 (9.5) | 3 (5.4) | 0.6 |
| Antifungal: voriconazole | 0 (0.0) | 2 (3.6) | 1.0 |
MMF, mycophenolate mofetil.